# GENETIC TOOLS AND CANCER

> **NIH NIH R01** · JACKSON LABORATORY · 1993 · $126,148

## Abstract

This research focuses on three major goals. One aspect of the proposed
studies is the continued development of genetic tools useful in the
analysis of susceptibility to cancer and other diseases. The AKXD set of
recombinant inbred strains derived from the cross of high lymphoma AKR/J
strain and the low lymphoma DBA/2J strain have been developed,
characterized with respect to lymphoma and leukemia susceptibility, and
typed for numerous genetic markers.  Genetic markers on Chromosomes 4 and
5 have been implicated as contributing to tumor susceptibility. By typing
additional markers in this set of RI strains, we will attempt to identify
additional loci that determine tumor latency and tumor type (T-cell or B-
cell lymphoma).  A second major effort has been the development of the MEV
(multiple ecotropic virus) linkage testing stock. The purpose of this
stock is to provide multiple easily typed genetic markers that can be
followed in crosses with other strains, facilitating the mapping of new
mutations and strain differences such as cancer susceptibility. This stock
has been selected for multiple copies of the endogenous ecotropic murine
leukemia virus genome widely dispersed markers in the mouse genome. These
proviruses can be individually scored in a single Southern blot. The best
current stock sweeps about 68% of the genome in a linkage cross.  Novel
proviruses are acquired in the stock by a process of germline infection
and 50 of these have been propagated to fixation as potential new markers.
Thirty of these have been mapped and ten are candidates for incorporation
into an ultimate linkage testing stock. Three of the proviral insertions
are associated with recessive phenotypes of unusual biomedical interest.
One of these insertional mutations is associated with male sterility.  The
provirus and flanking DNA sequences have been cloned and are being
analyzed as part of this program. A flanking genomic fragment detects a
testis-specific transcript. We propose to identify and characterize the
disrupted gene by cDNA cloning and sequencing and to investigate the
mechanism by which the provirus inhibits gene expression.  This mutation
may provide a useful model for the further analysis of the complex process
of spermatogenesis and lead to a better understanding of cases of human
infertility.

## Key facts

- **NIH application ID:** 3171024
- **Project number:** 2R01CA033093-12
- **Recipient organization:** JACKSON LABORATORY
- **SAM.gov UEI:** XR6LMXNKDJJ1
- **Principal Investigator:** BENJAMIN A TAYLOR
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1993
- **Award amount:** $126,148
- **Award type:** 2
- **Project period:** 1982-09-01 → 1998-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171024

## Citation

> US National Institutes of Health, RePORTER application 3171024, GENETIC TOOLS AND CANCER (2R01CA033093-12). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171024. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*